Hanmi’s Licensing Success Driven By Strong Clinical Strategy
This article was originally published in PharmAsia News
Hanmi Pharm's recent record license agreements with multinational pharma giants clearly show that the company may be a step or two ahead of its South Korean rivals in R&D and also indicate its strength in oncology. A local brokerage notes its clinical development strategy may also have played a role in this success and suggests ways other domestic pharmas can reduce failures.
You may also be interested in...
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.